Key Takeaways
- Stabilization quarter with a margin promise: Revenue of ₹337 Crores held at ~80% of peak run rate while gross margin improved sequentially to 41.6%, and management committed to reaching ~50% by Q4.
- Vizag is the central turnaround story: Validation supplies have begun, under-recovery is running at ₹10–11 Crores per quarter, and the explicit goal is for the site to stop being a P&L burden by Q4.
- Regulated markets mix is shifting up: Regulated markets rose to 66% of sales from 58% in FY2022, while the company is walking away from low-price business in less regulated markets.
- Debt reduction has started: Debt fell ₹11.7 Crores sequentially with no fresh loans, and net current assets dropped ₹50 Crores on inventory reduction, signaling a cash-flow-first posture.
- What to watch next quarter: Whether the promised raw material cost normalization materializes, the pace of Vizag customer filings and inspection triggers, and any movement on Cuddalore’s OAI reclassification.
The Vizag Turnaround
- Validation supplies underway: The company has initiated validation supplies to customers from the Vizag site, the step required to trigger regulatory inspections and unlock commercial approvals.
- Under-recovery drag quantified: Vizag under-recovery is running at ₹10–11 Crores per quarter and is expected to stay at that level until improvement begins; management targets the site becoming net from Q4 of this fiscal year.
- Filing roadmap: One new product filing from Vizag is planned for this quarter, another for Q3, and the ambition is to do at least three to four filings a year from the site.
- Regulatory inspection timeline: The plan is to amend DMFs to include the Vizag site by October; customers are then expected to trigger inspections, with a USFDA inspection targeted for the second half of next fiscal year and a European inspection possibly earlier.
- Less regulated market sales from Vizag: The company is targeting commencement of sales to less regulated markets or markets with no regulatory binding from Q3 of this fiscal year; currently no such sales flow from Vizag but opportunities are being explored.
- Incremental, not shifted, sales: Management clarified that expected Vizag sales are incremental and do not represent a shift of volume from existing facilities.
Jitesh Devendra: "The way we have mapped our business plan for Vizag the goal is by Q4 of this fiscal year the Vizag under recovery will not be a burden on our P&L."
Margin Recovery Path
- Sequential gross margin improvement: Gross margin rose to 41.6% in Q1 from Q4 FY2022 levels, driven by cost improvement programmes beginning to show results, though RM price increases and Vizag under-recovery continued to weigh.
- The 50% target: Management stated gross margins will not decline from here and plans to get closer to, or achieve, 50% gross margin by Q4 of this fiscal year, a level the company historically delivered as a minimum.
- Cost improvement programmes: The company has added more high-volume products under its cost improvement basket and is using these programmes to protect gross margin even if raw material prices rise further; the programmes also underpin competitiveness in price-sensitive less regulated markets.
- Raw material cost normalization expected: Raw material price increases faced in Q1 are expected to normalize in the current quarter, removing one headwind.
- Fixed cost levers are narrow: Fixed costs consist of plant operating costs and manpower; beyond energy, waste disposal cost reduction, and yield or process improvements, limited optimization scope exists.
Jitesh Devendra: "We do not see the gross margins declining we only see the gross margins improving and in the second half of this fiscal year it will be better than currently reported results."
Product & Market Mix
- Regulated markets share rising: Regulated markets sales increased to 66% of total revenue in Q1 FY2023 from 58% in FY2022, reflecting improving offtake for main products; the sequential dip in regulated markets was demand-driven, not price-driven, and prices have stabilized.
- Less regulated markets selectivity: Sales declined in less regulated markets because the company is foregoing opportunities where price does not meet its criteria, focusing only on products where cost improvement programmes make it competitive.
- Ibuprofen demand recovery underway: Demand is increasing, but returning to historical levels will take approximately six months; pricing is not expected to decline further from current levels.
- Two products under short-term pressure: Softening demand and raw material cost increases tied to the international situation are creating short-term challenges for two key products.
- New product definition: New products are those within three years of customer approval plus validation batches sold to customers; after three years they are reclassified as base products.
- Channel strategy unchanged: Less regulated markets represent an additional opportunity, not a strategy change; the majority of business is direct, though some markets require channel partners.
CRAMS & Business Development
- CRAMS revenue mix shift: CRAMS share declined sequentially from 7% to 5% of revenue; contract manufacturing is on track with no decline, but contract research is project-based and revenue pauses between project completion and customer next steps.
- Growth target: CRAMS is expected to contribute 8 to 10% of total revenues by FY2024, and on an annual basis the business will be on a growth path.
- BD team build-out: A dedicated business development position with significant CRAMS experience was recently hired in the US, and a dedicated BD team is now in place for both Europe and the US.
- Technology investment deferred: Investing in newer technologies for CRAMS is planned for next fiscal year, after course-correcting the current business; the company is tapping longstanding relationships with big pharma and emerging biotech and seeing newer opportunities from existing and new clients.
- Acquisition stance: Focus is on resetting the current business and utilizing current assets well before considering any acquisitions; having an asset in the West would be ideal but is not a current priority.
Jitesh Devendra: "I think where we stand out is in terms of our quality policy as well as the EHS these are the two important factors and of course the reliability and supply which is standard which everyone would ask for."
Regulatory & Site Developments
- Cuddalore OAI status: Ten new approvals are pending reclassification of the Cuddalore OAI status; management is hopeful of reclassification after a USFDA inspection expected in the near term.
- Alternate site qualification: Steps have been taken to qualify an alternate site within the manufacturing network for some key products manufactured in Cuddalore, with significant traction from new customers.
- R&D pipeline: Over 15 new programmes have been added for the year, the company is on track to file six new DMFs in FY2023, and more high-volume products have been added under the cost improvement basket.
- Brazil commercial timeline: Commercial sales from Brazil will start kicking in from FY2025.
- LATAM, Middle East, CIS growth: These three markets are expected to contribute to higher growth in the coming fiscal years.
Balance Sheet & Cash Flow
- Debt reduction begun: After debt increased over 50% in FY2022, Q1 FY2023 saw a reduction of ₹11.7 Crores with no fresh loans taken.
- Net current assets reduced: Net current assets fell by ₹50 Crores in Q1, primarily driven by inventory reduction, consistent with the stated primary focus on improving cash flows through prudent application of capital.
- Revenue run rate target: The short-term goal is to return to the historical run rate of ₹400 Crores per quarter, targeting Q4 of this fiscal year on an annualized basis.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Gross margin | Reach closer to or achieve 50% | Q4 FY23 |
| Vizag P&L burden | Vizag under-recovery eliminated; site net breakeven | Q4 FY23 |
| Vizag under-recovery run rate | Remain at ₹10–11 Crores/quarter until improvement begins | Next quarter |
| Vizag less regulated market sales | Commence sales to markets with no regulatory binding | Q3 FY23 |
| Vizag DMF amendments | Amend DMFs to include Vizag site | October FY23 |
| USFDA inspection (Vizag) | Inspection triggered by customers | Second half of next fiscal year |
| Ibuprofen demand | Return to historical demand levels | ~6 months |
| Brazil commercial sales | Commercial sales begin | FY2025 |
| CRAMS revenue share | Contribute 8–10% of total revenues | FY2024 |
| Revenue run rate | Return to historical ₹400 Crores/quarter (annualized) | Q4 FY23 |
| Raw material costs | Normalization of price increases faced | Current quarter |
Key Metrics
| Metric | Q1 FY23 |
|---|---|
| Revenue | ₹337 cr, approximately 80% of historical peak quarterly run rate |
| Gross margin | 41.6% |
| EBITDA | ₹18.1 cr |
| EBITDA margin | 5.4% |
| Regulated markets revenue share | 66% of total revenue, up from 58% in FY2022 |
| CRAMS revenue share | ~5% of total revenue, down from 7% in Q4 FY22 |
| New product sales share | 5% to 6% of total sales |
| Debt reduction | ₹11.7 cr reduced in Q1, no fresh loans availed |
| Net current assets reduction | ₹50 cr reduced in Q1, primarily due to inventory reduction |
| Net debt to EBITDA ratio target | Under 3.5x, based on annualized Q4 EBITDA |
| Fixed cost run rate | ~₹120 cr |
| Vizag under recovery | ~₹10 to 11 cr per quarter (per an analyst's math, confirmed by management) |
| DMF filings planned for FY23 | 6 new DMFs, of which 2 from Vizag |
| Vizag product filings capacity | At least 4 product filings per year |
| Q4 FY23 revenue target | ~₹400 cr quarterly run rate on annualized basis |
| Q4 FY23 gross margin target | ~50% |